pharmaceutical investing New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
pharmaceutical investing Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis
pharmaceutical investing Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
pharmaceutical investing Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
pharmaceutical investing Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
Canadians Living with Primary Biliary Cholangitis One Step Closer to New Treatment Option as Gilead Reaches Milestone National Agreement for LYVDELZI®
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver